company background image
IDRS.F logo

Idorsia OTCPK:IDRS.F Stock Report

Last Price

US$1.50

Market Cap

US$133.4m

7D

0%

1Y

-34.8%

Updated

23 Dec, 2024

Data

Company Financials +

IDRS.F Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. More details

IDRS.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Idorsia Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Idorsia
Historical stock prices
Current Share PriceCHF 1.50
52 Week HighCHF 2.88
52 Week LowCHF 0.81
Beta1.26
1 Month Change85.19%
3 Month Changen/a
1 Year Change-34.78%
3 Year Change-92.51%
5 Year Change-95.16%
Change since IPO-91.67%

Recent News & Updates

Recent updates

Shareholder Returns

IDRS.FUS BiotechsUS Market
7D0%-3.8%-2.7%
1Y-34.8%-2.6%23.4%

Return vs Industry: IDRS.F underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: IDRS.F underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is IDRS.F's price volatile compared to industry and market?
IDRS.F volatility
IDRS.F Average Weekly Movementn/a
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: IDRS.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IDRS.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/an/awww.idorsia.com

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia.

Idorsia Ltd Fundamentals Summary

How do Idorsia's earnings and revenue compare to its market cap?
IDRS.F fundamental statistics
Market capUS$133.39m
Earnings (TTM)-US$331.95m
Revenue (TTM)US$83.00m

1.6x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IDRS.F income statement (TTM)
RevenueCHF 74.12m
Cost of RevenueCHF 186.54m
Gross Profit-CHF 112.41m
Other ExpensesCHF 184.01m
Earnings-CHF 296.43m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)-1.57
Gross Margin-151.66%
Net Profit Margin-399.92%
Debt/Equity Ratio-100.5%

How did IDRS.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:13
End of Day Share Price 2024/12/13 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Idorsia Ltd is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maria MaldonadoBank Vontobel AG
Jean-Philippe BertschyBank Vontobel AG
Rosie TurnerBarclays